

Sociodemographic, clinical and pharmacological characteristics associated with the prognosis of patients with SARS-CoV-2 infection (Características sociodemográficas, clínicas y farmacológicas asociadas con el pronóstico en pacientes con infección por SARS-CoV-2)

First published: 15/09/2020

Last updated: 22/02/2023

Study

Finalised

Administrative details

EU PAS number

EUPAS37205

Study ID

39853

DARWIN EU® study

No

Study countries

☐ Spain

Study description

Study to assess the sociodemographic, clinical and pharmacological characteristics of patients with COVID19 in Catalonia, Spain, with data from SIDIAP database.

Study status

Finalised

Research institutions and networks

Institutions

Fundació Institut Universitari per a la Recerca a l'Atenció Primària de Salut Jordi Gol i Gurina, IDIAPJGol

☐ Spain

First published: 05/10/2012

Last updated: 23/05/2025

Institution

Educational Institution

Laboratory/Research/Testing facility

Not-for-profit

ENCePP partner

Contact details

Study institution contact

Giner-Soriano Maria mginer@idiapjgol.info

Study contact

mginer@idiapjgol.info

Primary lead investigator

Morros Pedrós Rosa

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 04/05/2020

Actual: 01/06/2020

Study start date

Planned: 01/06/2020

Actual: 10/08/2020

Data analysis start date

Planned: 21/09/2020

Actual: 31/10/2020

Date of final study report

Planned: 30/11/2020

Actual: 31/12/2020

Sources of funding

- Other

More details on funding

IDIAPJGol

Study protocol

[Covid_idiap_202009.pdf](#) (277.92 KB)

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study topic:

Human medicinal product

Disease /health condition

Study type:

Non-interventional study

Scope of the study:

Assessment of risk minimisation measure implementation or effectiveness

Disease epidemiology

Drug utilisation

Effectiveness study (incl. comparative)

Data collection methods:

Secondary use of data

Main study objective:

Assess infection rate for SARS-CoV-2 and describe sociodemographic, clinical and pharmacological characteristics.

Study Design

Non-interventional study design

Cohort

Study drug and medical condition

Anatomical Therapeutic Chemical (ATC) code

(J07BC20) combinations

combinations

Medical condition to be studied

COVID-19

Population studied

Short description of the study population

Patients diagnosed with COVID-19 identified from the SIDIAP database for the study period of January 2020 to April 2020.

Age groups

Preterm newborn infants (0 – 27 days)

Term newborn infants (0 – 27 days)

Infants and toddlers (28 days – 23 months)

Children (2 to < 12 years)

Adolescents (12 to < 18 years)

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

Special population of interest

Immunocompromised

Other

Special population of interest, other

COVID-19 patients

Estimated number of subjects

800000

Study design details

Outcomes

Infection rate for SARS-CoV-2, Association between sociodemographic, clinical and pharmacological characteristics with the prognosis of COVID19 patients

Data analysis plan

Exploration of events, logistic conditional regression, risk estimation

Documents

Study publications

[Dan Ouchi, Carles Vilaplana-Carnerero, Vanessa de Dios, Maria Giner-Soriano, Ro...](#)

[Cordero FM, Monné SB, Ortega JA, Contreras-Martos S, Ouchi D, Giner-Soriano M, ...](#)

[Maria Giner-Soriano, Ainhoa Gomez-Lumbreras, Cristina Vedia, Dan Ouchi, Rosa Mo...](#)

[Giner-Soriano M, de Dios V, Ouchi D, Vilaplana-Carnerero C, Monteagudo M, Morro...](#)

[Carl Llor, Dan Ouchi, Maria Giner-Soriano, Ana García-Sangenís, Lars Bjerrum, R...](#)

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025.
The ENCePP Seal fields are retained in the display mode for transparency

but are no longer maintained.

Data sources

Data source(s)

The Information System for Research in Primary Care (SIDIAP)

Data source(s), other

SIDIAP

Data sources (types)

[Drug dispensing/prescription data](#)

[Electronic healthcare records \(EHR\)](#)

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No